Using advanced MRI to improve radiotherapy for glioblastoma
Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma
This study is testing if using advanced MRI can help create a more accurate treatment area for radiotherapy in patients with glioblastoma, aiming to reduce side effects and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Rotterdam, Zuid-Holland) |
| Trial ID | NCT05970757 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance radiotherapy treatment for patients with IDH-wildtype glioblastoma by utilizing advanced MRI techniques to create a more precise clinical target volume (CTV). Currently, CTVs are determined using conventional imaging that may include healthy tissue, leading to unnecessary side effects from radiation. The study will focus on generating a physiological CTV that accounts for microscale tumor invasion while sparing healthy tissue. By doing so, it seeks to improve treatment outcomes and quality of life for patients undergoing radiotherapy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with IDH-wildtype glioblastoma who are referred for standard high-dose radiotherapy.
Not a fit: Patients with contraindications for MRI or gadolinium-based contrast agents, or those unable to provide informed consent, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce side effects of radiotherapy and improve the quality of life for glioblastoma patients.
How similar studies have performed: While the use of advanced MRI techniques in radiotherapy is gaining interest, this specific approach to generating a physiological CTV is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent; * Adults (18 years or older); * diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy; * referred to outpatient clinic of the Department of Radiotherapy to undergo standard treatment with high-dose RT. * Patients eligible for 30x2Gy or 15x2.67Gy Exclusion Criteria: * Contraindication for MRI * Contraindication for use of gadolinium-based contrast agent (i.e. subject having renal deficiency) * Unable to give informed consent
Where this trial is running
Rotterdam, Zuid-Holland
- Erasmus Medical Center — Rotterdam, Zuid-Holland, Netherlands (Recruiting)
Study contacts
- Study coordinator: Patrick Tang, MSc
- Email: p.l.y.tang@erasmusmc.nl
- Phone: +31634271995
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.